Drugs / VSV-IFNβ-NIS
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06508463 | Jan 2024 → Dec 2028 expected | anaplastic large cell lymphoma, mycosis fungoides, peripheral T-cell lymphoma, not otherwise specified | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 1 | NCT02923466 | Apr 2017 → Feb 2022 | cancer | Vyriad, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03647163 | Apr 2019 → Jul 2025 overdue | neuroendocrine carcinoma, non-small cell lung carcinoma, renal cell carcinoma | Vyriad, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VSV-IFNβ-NIS | “VSV-IFNβ-NIS as a single agent was effective in patients with TCL, resulting in durable disease remissions in heavily pretreated patients.” PMID 35175355 ↗ Jun 2022 |
| Route | Other | “VSV-IFNβ-NIS will be administered intratumorally as a single dose on day 1.” NCT02923466 ↗ |